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experiment, the treatment started 15 weeks after surgery in
established chronic renal insufficiency. This situation more
resembles the clinical renal disease, and may explain the
differences in the observed results.
We conclude that paricalcitol treatment does not always
suppress RAS components in the kidney, and suggest that the
observed effects of paricalcitol on RAS gene expression in
remnant kidneys may depend on the timing of the treatment.
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The comments by Karavalakis et al. refer to their
experiments in which paricalcitol administration was
delayed for 15 weeks following 5/6 nephrectomy and
maintained for 12 weeks.1 In the supplementary table
provided in their above letter, reverse transcription–PCR
determinations of various renin-angiotensin system (RAS)
components were not modified by paricalcitol treatment
and they suggest that the suppression of the RAS
components in our experiments is related to a nonspecific
postsurgical reduction of gene expression and/or the
timing of the therapeutic intervention.
To be noted, in their work reverse transcription–PCR
determinations of several RAS components display incon-
sistent directional variability with either up- or down-
regulated levels in kidney tissues of both treated and
untreated nephrectomized animals compared to sham.
Their findings of simultaneous downregulation of AT1R
and AT2R as well as that of the renin receptor in the
remnant kidney are in contrast with the results of others2,3
as well as ours.4 If what they observed is confirmed, then
the question is whether the ability of paricalcitol to
suppress an already downregulated genetic system in
kidneys with advanced chronic kidney disease is detect-
able. Unfortunately, neither renin nor additional RAS
genes mRNA or their protein expressions are shown, and
no indication about effects of functional or histopatholo-
gical changes in the remnant kidney by the delayed
paricalcitol treatment is given.
It is not clear what the authors mean by the shock
produced by the nephrectomy and its effects on gene
expression, because this is a well established experimental
model employed to evaluate the effects of early therapeutic
intervention on multiple molecular markers linked to
progressive chronic renal insufficiency.3 Furthermore, in
our own experiments,4 there was not a universal suppres-
sion of the renal mRNAs of the RAS but a specific
reduction in only some components, which argues against
a postsurgical nonspecific inhibition.
We agree with Karavalakis et al. that as we started
paricalcitol 4 days after nephrectomy and they started 15
weeks later, the experiments are not strictly comparable
and the timing of the therapeutic intervention could be the
reason for the differences between our results and theirs.
Unpublished observations in our laboratories indicate that
delaying paricalcitol treatment for 8 weeks after nephrect-
omy essentially abrogates the functional and histological
improvement of vitamin D analogues in the renal ablation
model.
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